Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

PET/CT of cancer patients: part 1, pancreatic neoplasms.

Dibble EH, Karantanis D, Mercier G, Peller PJ, Kachnic LA, Subramaniam RM.

AJR Am J Roentgenol. 2012 Nov;199(5):952-67. doi: 10.2214/AJR.11.8182. Review.

PMID:
23096166
2.

The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.

Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, Glanville J, McIntosh H, Renehan A, Weller D, Dunlop M.

Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350. Review.

3.

Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.

Asagi A, Ohta K, Nasu J, Tanada M, Nadano S, Nishimura R, Teramoto N, Yamamoto K, Inoue T, Iguchi H.

Pancreas. 2013 Jan;42(1):11-9. doi: 10.1097/MPA.0b013e3182550d77.

4.

Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.

Ergul N, Gundogan C, Tozlu M, Toprak H, Kadıoglu H, Aydin M, Cermik TF.

Rev Esp Med Nucl Imagen Mol. 2014 May-Jun;33(3):159-64. doi: 10.1016/j.remn.2013.08.005. Epub 2013 Oct 17.

5.

FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.

Parikh U, Marcus C, Sarangi R, Taghipour M, Subramaniam RM.

PET Clin. 2015 Jul;10(3):327-43. doi: 10.1016/j.cpet.2015.03.001. Epub 2015 Apr 16. Review.

PMID:
26099670
6.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
7.

Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors.

De Gaetano AM, Rufini V, Castaldi P, Gatto AM, Filograna L, Giordano A, Bonomo L.

Abdom Imaging. 2012 Dec;37(6):983-1003. doi: 10.1007/s00261-012-9845-y. Review.

PMID:
22527152
8.
9.

18 F-FDG PET/CT influences management in patients with known or suspected pancreatic cancer.

Barber TW, Kalff V, Cherk MH, Yap KS, Evans P, Kelly MJ.

Intern Med J. 2011 Nov;41(11):776-83. doi: 10.1111/j.1445-5994.2010.02257.x. Epub 2010 May 11.

PMID:
20492008
10.

Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.

Herrmann K, Erkan M, Dobritz M, Schuster T, Siveke JT, Beer AJ, Wester HJ, Schmid RM, Friess H, Schwaiger M, Kleeff J, Buck AK.

Eur J Nucl Med Mol Imaging. 2012 May;39(5):846-51. doi: 10.1007/s00259-012-2061-8. Epub 2012 Jan 26.

PMID:
22278320
11.

Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.

Buchs NC, Bühler L, Bucher P, Willi JP, Frossard JL, Roth AD, Addeo P, Rosset A, Terraz S, Becker CD, Ratib O, Morel P.

J Gastroenterol Hepatol. 2011 Apr;26(4):657-62. doi: 10.1111/j.1440-1746.2010.06525.x.

PMID:
21155879
12.

The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.

Kim MJ, Lee KH, Lee KT, Lee JK, Ku BH, Oh CR, Heo JS, Choi SH, Choi DW.

Pancreas. 2012 Aug;41(6):897-903. doi: 10.1097/MPA.0b013e318252f4f5.

PMID:
22699202
13.

Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).

Cameron K, Golan S, Simpson W, Peti S, Roayaie S, Labow D, Kostakoglu L.

Abdom Imaging. 2011 Aug;36(4):463-71. doi: 10.1007/s00261-011-9729-6. Review.

PMID:
21465110
14.

Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.

Santhosh S, Mittal BR, Bhasin D, Srinivasan R, Rana S, Das A, Nada R, Bhattacharya A, Gupta R, Kapoor R.

J Gastroenterol Hepatol. 2013 Feb;28(2):255-61. doi: 10.1111/jgh.12068.

PMID:
23278193
15.

Variability of target and normal structure delineation using multimodality imaging for radiation therapy of pancreatic cancer.

Dalah E, Moraru I, Paulson E, Erickson B, Li XA.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):633-40. doi: 10.1016/j.ijrobp.2014.02.035. Epub 2014 Apr 20.

PMID:
24755533
16.

Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis.

Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CH.

Eur J Surg Oncol. 2014 Jul;40(7):794-804. doi: 10.1016/j.ejso.2014.03.016. Epub 2014 Apr 3. Review.

PMID:
24755095
17.

¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases.

Nguyen VX, Nguyen CC, Nguyen BD.

JOP. 2011 Nov 9;12(6):557-66. Review.

18.

Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.

Goodfellow H, Viney Z, Hughes P, Rankin S, Rottenberg G, Hughes S, Evison F, Dasgupta P, O'Brien T, Khan MS.

BJU Int. 2014 Sep;114(3):389-95. doi: 10.1111/bju.12608. Epub 2014 Apr 16.

19.
20.

Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis.

Tang S, Huang G, Liu J, Liu T, Treven L, Song S, Zhang C, Pan L, Zhang T.

Eur J Radiol. 2011 Apr;78(1):142-50. doi: 10.1016/j.ejrad.2009.09.026. Epub 2009 Oct 23.

PMID:
19854016

Supplemental Content

Support Center